Skanska signs contract for next phase of Novartis Cambridge Campus Expansion Project, USA, worth USD 130 M, about SEK 848 M

8/22/2013 8:30 AM CET
Press release

Skanska has signed a contract for the next phase of work with existing client Novartis for the expansion of its pharmaceutical research campus located in Cambridge, MA, USA. The contract value is USD 130 M, about SEK 848 M, which will be included in order bookings for Skanska USA Building for the third quarter of 2013.

Work on the project began in 2012 and is scheduled to be completed in 2015.

Skanska USA is one of the leading development and construction companies in the country, consisting of four business units: Skanska USA Building, which specializes in building construction; Skanska USA Civil, specialized in civil infrastructure; Skanska Infrastructure Development, which develops public-private partnerships; and Skanska Commercial Development, which develops commercial projects in select U.S. markets. Headquartered in New York, Skanska USA has approximately 8,300 employees and its 2012 revenues were SEK 37.3 billion.

Contact: Pontus Winqvist, Senior Vice President Group Corporate Finance & Control
Telephone +46104488851